BCBS Minnesota

Does BCBS Minnesota cover Ozempic?

Quick answer · Type 2 Diabetes

BCBS Minnesota covers Ozempic for type 2 diabetes with prior authorization on Employer / Commercial Insurance and ACA Marketplace.

  • Employer / Commercial Insurance: Covered (preferred drug). A1C of 6.5% or higher
  • ACA Marketplace: Covered (preferred drug). A1C of 6.5% or higher

Last verified June 5, 2026. Policy effective April 1, 2026. Source: Pa policy. How we verify this data →

Check your card for your exact plan →

Ozempic for Type 2 Diabetes

What BCBS Minnesota requires, by plan type. Open this indication on its own page →

Employer / Commercial Insurance

Covered (preferred drug)

What you need to qualify

  • A1C of 6.5% or higher
  • Lab results confirming eligibility

Qualification pathways

You can qualify through any one of these.

New Start — Preferred Agent

All of:

  • Diagnosis of type 2 diabetes mellitus
  • A1C >= 6.5% confirmed by lab test (lab results or medical records required)
  • Ozempic (semaglutide) is a preferred agent — no step therapy required
  • Age within FDA labeling for the requested indication OR support for use at patient's age
  • Patient will NOT use requested agent in combination with a DPP-4 inhibitor
  • Patient will NOT use requested agent in combination with another GLP-1 receptor agonist
  • Patient does NOT have any FDA labeled contraindications to Ozempic

Continuation of Therapy

All of:

  • Diagnosis of type 2 diabetes mellitus
  • A1C >= 6.5% confirmed by lab test
  • Ozempic is listed as eligible for continuation of therapy
  • Age within FDA labeling for the requested indication OR support for use at patient's age
  • Patient will NOT use requested agent in combination with a DPP-4 inhibitor
  • Patient will NOT use requested agent in combination with another GLP-1 receptor agonist
  • Patient does NOT have any FDA labeled contraindications to Ozempic

Plus any one of:

  • Patient has been treated with a preferred agent (not samples) within the past 90 days
  • Prescriber states patient has been treated with a preferred agent within the past 90 days (not samples) and is at risk if therapy is discontinued

Documentation to bring

  • Documentation of type 2 diabetes mellitus diagnosis
  • Lab result confirming A1C >= 6.5% (or medical records)
  • Attestation that patient will not use Ozempic in combination with a DPP-4 inhibitor
  • Attestation that patient will not use Ozempic in combination with another GLP-1 receptor agonist
  • Confirmation that patient has no FDA labeled contraindications to Ozempic
  • For continuation: documentation or prescriber statement of prior preferred agent use within past 90 days (samples not approvable)

Quantity limits

  • 2 MG/3ML, 4 MG/3ML, 8 MG/3ML — 1 pen

Approval and renewal

  • Initial approval: 12 months
  • Renewal: every 12 months

Not covered when

  • Combination use with DPP-4 inhibitor agents
  • Combination use with another GLP-1 receptor agonist
  • FDA labeled contraindications to Ozempic (personal or family history of MTC or MEN2; prior serious hypersensitivity)

Policy note: Ozempic (semaglutide) is listed as a preferred agent. The FDA label also includes indications for CV risk reduction and CKD in T2DM patients, but this PA policy document only establishes criteria under a diabetes (glycemic control) module — no separate CV risk reduction or CKD criteria are established in this document. The BCBS MN Step Therapy Supplement also applies. Quantity limit: 1 pen per 28 days across all strengths.

Policy effective April 1, 2026 · verified June 5, 2026 · source: Pa policy

ACA Marketplace

Covered (preferred drug)

What you need to qualify

  • A1C of 6.5% or higher
  • Lab results confirming eligibility

Qualification pathways

You can qualify through any one of these.

New Start — Preferred Agent

All of:

  • Diagnosis of type 2 diabetes mellitus
  • A1C >= 6.5% confirmed by lab test (lab results or medical records required)
  • Ozempic (semaglutide) is a preferred agent — no step therapy required
  • Age within FDA labeling for the requested indication OR support for use at patient's age
  • Patient will NOT use requested agent in combination with a DPP-4 inhibitor
  • Patient will NOT use requested agent in combination with another GLP-1 receptor agonist
  • Patient does NOT have any FDA labeled contraindications to Ozempic

Continuation of Therapy

All of:

  • Diagnosis of type 2 diabetes mellitus
  • A1C >= 6.5% confirmed by lab test
  • Ozempic is listed as eligible for continuation of therapy
  • Age within FDA labeling for the requested indication OR support for use at patient's age
  • Patient will NOT use requested agent in combination with a DPP-4 inhibitor
  • Patient will NOT use requested agent in combination with another GLP-1 receptor agonist
  • Patient does NOT have any FDA labeled contraindications to Ozempic

Plus any one of:

  • Patient has been treated with a preferred agent (not samples) within the past 90 days
  • Prescriber states patient has been treated with a preferred agent within the past 90 days (not samples) and is at risk if therapy is discontinued

Documentation to bring

  • Documentation of type 2 diabetes mellitus diagnosis
  • Lab result confirming A1C >= 6.5% (or medical records)
  • Attestation that patient will not use Ozempic in combination with a DPP-4 inhibitor
  • Attestation that patient will not use Ozempic in combination with another GLP-1 receptor agonist
  • Confirmation that patient has no FDA labeled contraindications to Ozempic
  • For continuation: documentation or prescriber statement of prior preferred agent use within past 90 days (samples not approvable)

Quantity limits

  • 2 MG/3ML, 4 MG/3ML, 8 MG/3ML — 1 pen

Approval and renewal

  • Initial approval: 12 months
  • Renewal: every 12 months

Not covered when

  • Combination use with DPP-4 inhibitor agents
  • Combination use with another GLP-1 receptor agonist
  • FDA labeled contraindications to Ozempic (personal or family history of MTC or MEN2; prior serious hypersensitivity)

Policy note: Ozempic (semaglutide) is listed as a preferred agent. The FDA label also includes indications for CV risk reduction and CKD in T2DM patients, but this PA policy document only establishes criteria under a diabetes (glycemic control) module — no separate CV risk reduction or CKD criteria are established in this document. The BCBS MN Step Therapy Supplement also applies. Quantity limit: 1 pen per 28 days across all strengths.

Policy effective April 1, 2026 · verified June 5, 2026 · source: Pa policy

Ozempic for Heart Disease Risk Reduction

What BCBS Minnesota requires, by plan type. Open this indication on its own page →

Employer / Commercial Insurance

Covered (preferred drug)

What you need to qualify

  • Age 18 and older
  • A1C of 6.5% or higher
  • Diagnosis documented with a code
  • Established cardiovascular disease (MI, stroke, revascularization, TIA, unstable_angina, amputation, and coronary_artery_disease)
  • Lab results confirming eligibility

Qualification pathways

You can qualify through any one of these.

CV Risk Reduction - Ozempic in T2DM with Established CVD or Multiple CV Risk Factors

All of:

  • Diagnosis of type 2 diabetes
  • A1C >= 6.5% confirmed by lab test
  • Requested agent will be used to reduce risk of major adverse cardiovascular events (cardiovascular death, non-fatal MI, or non-fatal stroke)
  • Patient will NOT use requested agent in combination with a DPP-4 containing agent
  • Patient will NOT use requested agent in combination with another GLP-1 or GLP-1/GIP receptor agonist
  • No FDA labeled contraindications to the requested agent

Plus any one of:

  • Patient has established cardiovascular disease (e.g., MI, stroke, any revascularization procedure, TIA, unstable angina, amputation, symptomatic or asymptomatic coronary artery disease)
  • Patient has multiple cardiovascular risk factors (e.g., hypertension, dyslipidemia, family history of cardiovascular disease, smoking)

Documentation to bring

  • Documentation of type 2 diabetes diagnosis
  • Lab test results showing A1C >= 6.5%
  • Documentation of established cardiovascular disease (e.g., MI, stroke, revascularization, TIA, unstable angina, amputation, CAD) or documentation of multiple cardiovascular risk factors (HTN, dyslipidemia, family history of CVD, smoking)
  • Prescriber statement that the requested agent will be used to reduce risk of major adverse cardiovascular events
  • Confirmation that patient is not using a DPP-4 inhibitor concurrently
  • Confirmation that patient is not using another GLP-1 or GLP-1/GIP receptor agonist concurrently

Quantity limits

  • 2 MG/3ML — 1 pen per 28 days
  • 4 MG/3ML — 1 pen per 28 days
  • 8 MG/3ML — 1 pen per 28 days

Approval and renewal

  • Initial approval: 12 months
  • Renewal: every 12 months
  • To renew, the plan looks for Continuation approved via same criteria as initial approval. Patient must still have T2DM diagnosis and A1C >= 6.5%. Continuation pathway also available if patient has been on a preferred agent within past 90 days.

Not covered when

  • Concurrent use with DPP-4 inhibitors
  • Concurrent use with another GLP-1 or GLP-1/GIP receptor agonist
  • Personal or family history of MTC or MEN 2
  • Type 1 diabetes

Policy note: CV risk reduction indication for Ozempic applies in patients with T2DM and established CVD or multiple CV risk factors. The policy does not exclude patients who have NOT failed metformin/insulin if the CV risk pathway is used — metformin/insulin trial is NOT required for this pathway. T2DM diagnosis and A1C >= 6.5% are still required. This is a bundled policy covering all GLP-1 indications under a single PA framework; the CV risk pathway is a qualifying exception to the metformin/insulin step therapy requirement.

source: Pa policy

Ozempic for Kidney Disease (CKD)

What BCBS Minnesota requires, by plan type. Open this indication on its own page →

Employer / Commercial Insurance

Covered (preferred drug)

What you need to qualify

  • Age 18 and older
  • A1C of 6.5% or higher
  • Diagnosis documented with a code
  • Lab results confirming eligibility

Qualification pathways

You can qualify through any one of these.

CKD Indication - Ozempic in T2DM with CKD

All of:

  • Diagnosis of type 2 diabetes
  • A1C >= 6.5% confirmed by lab test
  • Patient has chronic kidney disease (CKD)
  • Requested agent will be used to reduce risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death
  • Patient will NOT use requested agent in combination with a DPP-4 containing agent
  • Patient will NOT use requested agent in combination with another GLP-1 or GLP-1/GIP receptor agonist
  • No FDA labeled contraindications to the requested agent

Documentation to bring

  • Documentation of type 2 diabetes diagnosis
  • Lab test results showing A1C >= 6.5%
  • Documentation of chronic kidney disease (CKD) diagnosis
  • Prescriber statement that the requested agent will be used to reduce risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death
  • Confirmation that patient is not using a DPP-4 inhibitor concurrently
  • Confirmation that patient is not using another GLP-1 or GLP-1/GIP receptor agonist concurrently

Quantity limits

  • 2 MG/3ML — 1 pen per 28 days
  • 4 MG/3ML — 1 pen per 28 days
  • 8 MG/3ML — 1 pen per 28 days

Approval and renewal

  • Initial approval: 12 months
  • Renewal: every 12 months
  • To renew, the plan looks for Continuation approved via same criteria as initial approval, or via the continuation of therapy pathway if patient has been on a preferred agent within past 90 days.

Not covered when

  • Concurrent use with DPP-4 inhibitors
  • Concurrent use with another GLP-1 or GLP-1/GIP receptor agonist
  • Personal or family history of MTC or MEN 2
  • Type 1 diabetes

Policy note: CKD indication for Ozempic (to reduce risk of sustained eGFR decline, ESKD, and cardiovascular death in T2DM with CKD) is recognized as an exception pathway to the metformin/insulin step therapy requirement. Specific eGFR or UACR thresholds are not defined in this policy document. T2DM diagnosis and A1C >= 6.5% are still required per the overall PA framework.

source: Pa policy

Why Ozempic requests get denied by BCBS Minnesota

Based on what this policy asks for. Fix these before the first submission.

  1. Wrong brand for the diagnosis. Ozempic and Wegovy are the same molecule with different approved uses; a request for Ozempic under a diagnosis that matches Wegovy is routinely denied.
  2. Diagnosis code missing or wrong on the request.
  3. No recent A1C result on file.

Frequently asked questions

Does BCBS Minnesota cover Ozempic?
BCBS Minnesota covers Ozempic for type 2 diabetes with prior authorization on Employer / Commercial Insurance and ACA Marketplace.
How long does a Ozempic approval last with BCBS Minnesota?
Initial approvals last 12 months, and renewals are granted in 12-month periods.
What does BCBS Minnesota require to renew Ozempic?
Continuation approved via same criteria as initial approval. Patient must still have T2DM diagnosis and A1C >= 6.5%. Continuation pathway also available if patient has been on a preferred agent within past 90 days.
How current is this information?
This page reflects BCBS Minnesota's written policy as of April 1, 2026, last verified against the source document on June 5, 2026.

Other medications under BCBS Minnesota

Ozempic coverage under other plans

All insurance plans · All medications

This page summarizes BCBS Minnesota's written prior-authorization policy. It is not a guarantee of coverage; plans vary by employer and benefit design. Verify with your plan before relying on it.